-

Agilent Names Michael Buckner as Chief Legal Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the appointment of Michael Buckner as chief legal officer, effective today.

Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments.

“We are thrilled to welcome Michael to the Agilent team,” said Padraig McDonnell, Agilent president and CEO. “His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and stakeholders worldwide.”

Buckner joins Agilent from Danaher Corp., where he served as vice president, deputy general counsel, and chief M&A counsel. In this role, he led legal strategy for mergers and acquisitions, antitrust, intellectual property transactions, and debt securities, while overseeing a global team. He played a central role in several high-profile transactions, including the acquisition of Abcam and the Veralto spin-off, while advising senior leadership and members of the board on legal strategy and risk management.

Previously, Buckner spent 16 years at General Electric in roles of increasing responsibility, most recently as vice president and chief counsel for mergers and acquisitions, where he served as the company’s lead mergers and acquisitions lawyer globally. Earlier in his career, he held legal roles at Capital One Financial Corp. and in private practice, where he focused on corporate and securities law.

Buckner holds a Bachelor of Arts in history and political science, with high honors, from Rutgers University, and a Juris Doctor from the University of Chicago Law School.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

INVESTOR CONTACT:
Tejas Savant
+1 302-633-8090
tejas.savant@agilent.com

MEDIA CONTACT:
Kate Coyle
+1 302-633-7490
kate.coyle@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

INVESTOR CONTACT:
Tejas Savant
+1 302-633-8090
tejas.savant@agilent.com

MEDIA CONTACT:
Kate Coyle
+1 302-633-7490
kate.coyle@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom